Optimi Health Corp. (OPTHF)
| Previous Close | 0.1466 |
| Open | 0.1490 |
| Bid | 0.1420 x 0 |
| Ask | 0.1490 x 0 |
| Day's Range | 0.1490 - 0.1490 |
| 52 Week Range | 0.1100 - 0.4300 |
| Volume | |
| Avg. Volume | 23,047 |
| Market Cap | 14.105M |
| Beta (5Y Monthly) | 1.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Optimi Health Announces First PTSD Patients Treated with MDMA Capsules in Australia
Additional 700 Doses Ordered by Mind Medicine Australia as Demand Surges Vancouver, British Columbia--(Newsfile Corp. - October 23, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in botanical psilocybin and MDMA, is proud to announce that the first group of patients with post-traumatic stress disorder (PTSD) in Australia has successfully received treatment with its GM
- Newsfile
Optimi Health Announces Leadership Transition
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics specializing in botanical psilocybin and MDMA, today announced that Mr. William (Bill) Ciprick will be stepping down as Chief Executive Officer due to personal reasons."During his three years of leadership, Bill has played a key role in bringing Optimi's GMP psychedelics to ma
